Predictors of family impact of juvenile localized scleroderma.
child
dermatology
family
localized
quality of life
rheumatology
scleroderma
Journal
Pediatric dermatology
ISSN: 1525-1470
Titre abrégé: Pediatr Dermatol
Pays: United States
ID NLM: 8406799
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
pubmed:
16
7
2021
medline:
11
11
2021
entrez:
15
7
2021
Statut:
ppublish
Résumé
To measure the impact juvenile localized scleroderma (jLS) has on family quality of life and to identify predictors of family impact in this population which may inform the development of tailored resources to enhance family functioning for patients with jLS. A retrospective cohort study of pediatric patients with jLS and their families was conducted. Five questionnaires were administered at each visit: Pediatric Quality of Life Inventory Family Impact Module (PedsQL-FIM), PedsQL 4.0 Generic Core Scales (PedsQL-Generic), PedsQL Rheumatology Module (PedsQL-RM), Child Health Assessment Questionnaire (CHAQ), and Children's Dermatology Life Quality Index (CDLQI). Linear mixed models with random intercepts for each patient were used to find relationships between family impact scores and clinically relevant variables over time. Variables of interest included disease activity status, methotrexate use, jLS distribution, and scores for PedsQL-Generic and PedsQL-RM. The median baseline PedsQL-FIM total score was 80.9 (IQR = 76.6-97.4). Adjusting for age and sex, the most significant predictors of family impact were PedsQL-Generic scores and four of five PedsQL-RM dimensions (all P < .001); methotrexate use had borderline significance (P = .06). Family impact increased more significantly over time in older patients. In multivariable modeling, PedsQL-Generic total score and jLS "other" distribution were significant for predicting an increased PedsQL-FIM score (P = .003 and P = .03, respectively). JLS has a moderate family impact. Family impact is predicted by patients' general and disease-specific health-related quality of life (HRQL) and their jLS subtype. There is a trend toward increased family impact with methotrexate treatment. This study emphasizes the importance of family-centered care in jLS.
Substances chimiques
Methotrexate
YL5FZ2Y5U1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1137-1142Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Zulian F, Athreya BH, Laxer R, et al. Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study. Rheumatology (Oxford). 2006;45(5):614-620.
Martini G, Fadanelli G, Agazzi A, Vittadello F, Meneghel A, Zulian F. Disease course and long-term outcome of juvenile localized scleroderma: experience from a single pediatric rheumatology Centre and literature review. Autoimmun Rev. 2018;17(7):727-734.
Murray KJ, Laxer RM. Scleroderma in children and adolescents. Rheum Dis Clin North Am. 2002;28(3):603-624.
Zulian F, Vallongo C, Woo P, et al. Localized scleroderma in childhood is not just a skin disease. Arthritis Rheum. 2005;52(9):2873-2881.
Orzechowski NM, Davis DM, Mason TG, Crowson CS, Reed AM. Health-related quality of life in children and adolescents with juvenile localized scleroderma. Rheumatology (Oxford). 2009;48(6):670-672.
Ardalan K, Zigler CK, Torok KS. Predictors of longitudinal quality of life in juvenile localized scleroderma. Arthritis Care Res. 2017;69(7):1082-1087.
Das S, Bernstein I, Jacobe H. Correlates of self-reported quality of life in adults and children with morphea. J Am Acad Dermatol. 2014;70(5):904-910.
Uziel Y, Laxer RM, Krafchik BR, Yeung RSM, Feldman BM. Children with morphea have normal self-perception. J Pediatr. 2000;137(5):727-730.
Zulian F. Systemic sclerosis and localized scleroderma in childhood. Rheum Dis Clin North Am. 2008;34(1):239-255.
Schor EL. Family pediatrics: report of the task force on the family. Pediatrics. 2003;111(6):1541-1571.
Arkachaisri T, Vilaiyuk S, Li S, et al. The localized scleroderma skin severity index and physician global assessment of disease activity: a work in progress toward development of localized scleroderma outcome measures. J Rheumatol. 2009;36(12):2819-2829.
Arkachaisri T, Vilaiyuk S, Torok KS, Medsger TA. Development and initial validation of the localized scleroderma skin damage index and physician global assessment of disease damage: a proof-of-concept study. Rheumatology (Oxford). 2010;49(2):373-381.
Varni JW, Sherman SA, Burwinkle TM, Dickinson PE, Dixon P. The PedsQLTM family impact module: preliminary reliability and validity. Health Qual Life Outcomes. 2004;2:55.
Varni JW, Seid M, PedsQLTM KPS. 4.0: reliability and validity of the Pediatric Quality of Life InventoryTM version 4.0 generic core scales in healthy and patient populations. Med Care. 2001;39(8):800-812.
Varni JW. Scaling and scoring of the Pediatric Quality of Life InventoryTM (PedsQLTM). Available from: https://www.pedsql.org/PedsQL-Scoring.pdf Accessed May 21, 2019
Varni JW, Seid M, Knight TS, Burwinkle T, Brown J, Szer IS. The PedsQLTM in pediatric rheumatology: reliability, validity, and responsiveness of the Pediatric Quality of Life InventoryTM generic core scales and rheumatology module. Arthritis Rheum. 2002;46(3):714-725.
Singh G, Athreya BH, Fries JF, Goldsmith DP. Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum. 1994;37(12):1761-1769.
Lewis-Jones MS, Finlay AY. The Children’s Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol. 1995;132(6):942-949.
Holme SA, Man I, Sharpe JL, Dykes PJ, Lewis-Jones MS, Finlay AY. The children’s dermatology life quality index: validation of the cartoon version. Br J Dermatol. 2003;148(2):285-290.
R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2020. Available from: http://www.R-project.org/ Accessed May 29, 2020
de Kloet AJ, Lambregts SAM, Berger MAM, Van Markus F, Wolterbeek R, Vliet Vlieland TPM. Family impact of acquired brain injury in children and youth. J Dev Behav Pediatr. 2015;36(5):342-351.
Kountz-Edwards S, Aoki C, Gannon C, Gomez R, Cordova M, Packman W. The family impact of caring for a child with juvenile dermatomyositis. Chronic Illn. 2017;13(4):262-274.
Wallander JL, Varni JW. Effects of pediatric chronic physical disorders on child and family adjustment. J Child Psychol Psychiatry. 1998;39(1):29-46.
Zigler CK, Ardalan K, Hernandez A, et al. Exploring the impact of paediatric localized scleroderma on health-related quality of life: focus groups with youth and caregivers. Br J Dermatol. 2020;183(4):692-701.
Szczęch J, Samotij D, Jaworecka K, Tobiasz A, Reich A. Quality of life in patients with morphea: a cross-sectional study and a review of the current literature. Biomed Res Int. 2020;2020:9186274.